CRVO occurs when blood can no longer travel through the main blood vessel that brings blood to the back of the eye. This can cause swelling, and it may lead to vision loss. The retina is a layer of ...

Tenecteplase failed to outperform aspirin for vision recovery when administered within 4.5 hours of onset of acute central retinal artery occlusion. The thrombolytic treatment increased safety risks, ...

– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...

Please provide your email address to receive an email when new articles are posted on . Patients maintained or exceeded baseline visual acuity at 1 year. Data showed reductions in central subfield ...

Recent media reports from Pakistan suggest that Imran Khan, the former Prime Minister and World Cup-winning captain, has reportedly lost nearly 85% of vision in his right eye due to central retinal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Vabysmo achieved positive safety and efficacy results in ...

‒ Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept – ‒ More Vabysmo patients showed an absence of blood ...

CHICAGO -- A novel antibody-biopolymer conjugate (ABC) achieved visual acuity comparable to aflibercept (Eylea) for retinal vein occlusion (RVO) with less frequent dosing, according to a randomized ...

We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving adults with acute, nonarteritic central retinal artery occlusion who had symptom onset within 4.5 hours ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...